Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Dermatologic 1

Conditions

Lung Neoplasms 23Carcinoma, Non-Small-Cell Lung 15Ovarian Neoplasms 13Fallopian Tube Neoplasms 12Carcinoma, Hepatocellular 9Colorectal Neoplasms 8Urinary Bladder Neoplasms 7Pancreatic Neoplasms 6Melanoma 6Lymphoma, Large B-Cell, Diffuse 6Mycosis Fungoides 5Leukemia, Lymphocytic, Chronic, B-Cell 5Carcinoma, Renal Cell 5Squamous Cell Carcinoma of Head and Neck 4Neoplasm Metastasis 4Lymphoma, T-Cell, Cutaneous 4Glioblastoma 4Colonic Neoplasms 4Breast Neoplasms 4Triple Negative Breast Neoplasms 3Thyroid Neoplasms 3Sezary Syndrome 3Rectal Neoplasms 3Nasopharyngeal Carcinoma 3Multiple Myeloma 3Mouth Neoplasms 3Lymphoma, T-Cell 3Lymphoma, B-Cell 3Endometrial Neoplasms 3Carcinoma 3

Interventions

Infliximab 3Fecal Microbiota Transplantation 3vedolizumab 2Prednisone 2LDP-02 2Immunoglobulin G 2Disulfides 2CT-P13 2prednylidene 1deltacortene 1Standard of Care 1Practice Guidelines as Topic 1Methylprednisolone Hemisuccinate 1Methylprednisolone 1Loperamide 1Endoscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Colitis × Disulfides × 1 year × Clear all
NCT03819296 2026-03-11

Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

M.D. Anderson Cancer Center

Phase 1 Recruiting
800 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Colitis, Lung Neoplasms, Urogenital Neoplasms

NCT04407247 2025-12-23

Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
47 enrolled
DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Colitis, Melanoma, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡